QDEL
Quidelortho Corp Health Care In Vitro & In Vivo Diagnostic Substances Russell 3000
$13.25Close
$899.7MMarket cap
$9.96 – $35.3852-week range
Nov 3, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 9 · weaker than 91% of stocks over 12 months
- Far from its high 63% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
63%
1wk
down 3.5%
price change
1mo
up 25.7%
price change
12-month return
down 51%
market up 11% ·
its own down 63%
F-score
—
— Not assessed
Altman Z
-0.05
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
0.5×
price / book
Earnings yield
down 26.8%
EBIT / enterprise value
Cheaper than
37%
of the market · expensive
Revenue growth
down 2%
year on year
EPS growth
—
latest quarter
Sales growth
up 3%
latest quarter · +13 pts
ROE
down 46%
return on equity
Free cash margin
down 3%
-$83.0M FCF
D/E
1.40
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.7%
$1.02 a day · 2×ATR $11.22
RS
9 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
0.79
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 2 of 8
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Revenue shrinking Revenue fell 1.9% over the year, from $2.8B to $2.7B.
Last reported
Aug 6, 2026
Last shock
Aug 7, 2026-25% in one session3.0× volumeon results+8% since
Financials
- Net -41%
- Free cash -3%
- Cash
- Long-term debt
| FY2020Jan 3, 2021 | FY2021Jan 2, 2022 | FY2022Jan 1, 2023 | FY2023Dec 31, 2023 | FY2024Dec 29, 2024 | FY2025Dec 28, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.7B | $3.3B | $3.0B | $2.8B | $2.7B |
| Operating income | $1.1B | $906.0M | $843.7M | $139.1M | -$2.0B | -$919.2M |
| Net income | $810.3M | $704.2M | $548.7M | -$10.1M | -$2.1B | -$1.1B |
| Net margin | 49% | 41% | 17% | -0% | -74% | -41% |
| Earnings per share | $18.58 | $16.41 | $9.56 | -$0.15 | -$30.54 | -$16.69 |
| Free cash flow | $564.8M | $513.1M | $744.4M | $70.9M | -$112.1M | -$83.0M |
| Free cash margin | 34% | 30% | 23% | 2% | -4% | -3% |
| Cash | $489.9M | $802.8M | $292.9M | $118.9M | $98.3M | $169.8M |
| Long-term debt | — | $400,000 | $2.6B | $2.4B | $2.5B | $2.7B |
| Shareholders' equity | $1.3B | $1.9B | $4.9B | $5.0B | $3.0B | $1.9B |
| Shares outstanding | — | 41.70m | 66.40m | 66.70m | 67.30m | 67.90m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 28, 2026 | 40d |
| May 6, 2026 | Quarterly ↗ | Mar 29, 2026 | 38d |
| Feb 19, 2026 | Annual ↗ | Dec 28, 2025 | 53d |
| Nov 6, 2025 | Quarterly ↗ | Sep 28, 2025 | 39d |
| Aug 6, 2025 | Quarterly ↗ | Jun 29, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 30, 2025 | 39d |
| Feb 27, 2025 | Annual ↗ | Dec 29, 2024 | 60d |
| Nov 8, 2024 | Quarterly ↗ | Sep 29, 2024 | 40d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 2, 2023 | Quarterly ↗ | Oct 1, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 23, 2026 | Material agreement ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 23, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 16, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Apr 15, 2026 | Results ↗ |
| Mar 24, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 13, 2026 | Director or officer change ↗ |
| Feb 11, 2026 | Results ↗ |
| Feb 5, 2026 | Director or officer change ↗ |
| Nov 10, 2025 | Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |